Check Credit Score
Check Credit Score
HomeNewsTrendsHealth

Sun Pharma acquires 3 brands to strengthen anti-inflammatory portfolio

Acquired from Aksigen Hospital, Disperzyme, Disperzyme-CD and Phlogam have been approved by the Drugs Controller General of India for post-operative inflammation in patients undergoing minor surgery and dental procedures

January 30, 2023 / 01:15 PM IST
The FDA has given Sun Pharma 15 working days to respond to the warning letter, address violations and prevent their recurrence (Representative Image)

The FDA has given Sun Pharma 15 working days to respond to the warning letter, address violations and prevent their recurrence (Representative Image)

 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Sun Pharma said on January 30 that it had acquired three drug brands from Mumbai-based Aksigen Hospital to strengthen its anti-inflammatory portfolio.

Disperzyme, Disperzyme-CD and Phlogam have been approved by the Drugs Controller General of India (DCGI) for post-operative inflammation in patients undergoing minor surgery and dental procedures, Sun Pharma said in a release.

The addition of Disperzyme and Phlogam would further strengthen the company's anti-inflammatory portfolio. "This systemic enzyme therapy combination is being used to control edema and it speeds up the healing process. In a comparative clinical trial in India, the brands provided significantly better control and resolution of post-operative pain and inflammation,” Kirti Ganorkar, CEO-India business, Sun Pharma, said.

According to the pharma firm, Disperzyme and Phlogam are the first enzyme-bioflavonoid combination of Trypsin, Bromelain and Rutoside (“TBR”) to complete a clinical study in India and get DCGI approval.

The brands were registered and launched in India by Aksigen in 2013.

As per the IQVIA November 2022 data, the overall market of proteolytic enzyme for healing, pain and edema in India is around Rs 500 crore.

At 1.11 pm, the stock was trading at Rs 1,046.80 on the National Stock Exchange, up 0.33 percent from the previous close.

Ayushman Kumar
Ayushman Kumar Covers health and pharma for MoneyControl.
first published: Jan 30, 2023 01:15 pm

Discover the latest business news, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347